Darmiyan has launched the BrainSee Platform, featuring the US Food and Drug Administration (FDA) approved BrainSee test for Alzheimer’s disease.
This marks a significant advancement in the diagnosis and monitoring of Alzheimer’s dementia risk, particularly for patients with amnestic mild cognitive impairment (aMCI).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In January this year, the FDA approved BrainSee, a software as a service (SaaS) platform that is poised to transform the approach to evaluating and tracking the likelihood of progression to Alzheimer’s dementia within five years.
The BrainSee test offers a departure from conventional Alzheimer’s assessments that typically depend on non-specific biomarkers such as amyloid or tau.
It is entirely non-invasive, has high accuracy, and targets prognosing aMCI, where memory loss is the primary symptom.
Darmiyan founding CEO Dr Padideh Kamali-Zare said: “With the BrainSee Platform, we are excited to offer a comprehensive infrastructure that, in addition to administering BrainSee Test, supports remote doctor visits and consultations, comprehensive cognitive assessments, MRI prescriptions, and follow-ups—all covered under Medicare with just a nominal out-of-pocket booking fee.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUtilising AI algorithms, the BrainSee test analyses routine clinical brain MRIs and cognitive test outcomes. It generates a numerical score from zero to 100, reflecting the patient’s risk of developing Alzheimer’s dementia within five years.
Scores under 50 indicate a low risk, providing patients with peace of mind, while scores above 50 signal a high risk, prompting early intervention and lifestyle changes to potentially avert or delay dementia.
Doctors may opt to repeat the test yearly or more frequently based on their discretion, to track risk alterations and evaluate the effectiveness of medical treatments and lifestyle adjustments in shifting a patient’s risk status from high to low.
From this month, healthcare providers across the US will have access to the BrainSee Platform, offering a new tool in the fight against Alzheimer’s disease.
